GLP-1 News — Week of July 20, 2026
The GLP-1 stories that mattered this week — each one summarised neutrally and linked to its primary source. Nothing here is influenced by advertisers.
FDA adds semaglutide and tirzepatide APIs to import alert, tightening oversight of compounded GLP-1 supply
FDA significantly revised Import Alert 66-80 to include GLP-1 active ingredients such as semaglutide and tirzepatide, allowing the agency to more easily detain and refuse suspect imports. FDA notes it has already reviewed 48 GLP-1 API manufacturing sites and cites concerns about adulterated or sub-potent ingredients feeding unapproved compounded products, which could reduce availability of some compounded GLP-1s while improving quality control. (2026-07-18)
Source: FDA
Related on Metabolic Ledger: /regulatory/where-to-get-compounded-glp1-2026
FDA updates safety communication on unapproved and compounded GLP-1 drugs with new adverse event reports
FDA refreshed its safety communication on unapproved GLP-1 products, especially compounded semaglutide and tirzepatide, adding adverse event and quality data through May 31, 2026. The update details overdosing tied to non-standard titration, injection-site issues, and products arriving warm or inadequately refrigerated, and reiterates that compounded GLP-1s should mainly be used when approved drugs are unavailable or inappropriate and only via licensed prescribers and pharmacies. (2026-07-22)
Source: FDA
Related on Metabolic Ledger: /drugs/compounded-vs-brand-glp1
Axios: tighter GLP-1 compounding rules push some clinics toward less regulated peptide injections
Axios reports that as FDA tightens oversight of compounded GLP-1 drugs and their ingredients, some compounders and wellness clinics are pivoting to other peptides that currently face fewer regulatory barriers. The piece notes that FDA's compounding review aims to limit mass-market use of compounded semaglutide and tirzepatide, raising the risk that patients may instead be offered alternative peptides with far less evidence and less clear safety profiles. (2026-07-23)
Source: Axios
Related on Metabolic Ledger: /regulatory/research-peptide-glp1-risks
Early Medicare GLP-1 Bridge data: many older adults choose injectable Wegovy and Zepbound over pills
A Reuters-based report describes early experience from the Medicare GLP-1 Bridge pilot, which from July 1, 2026 offers eligible beneficiaries Wegovy, Zepbound, and Foundayo for a fixed $50 monthly cost as obesity treatments. Clinicians and analysts observe that many older adults are opting for injectable GLP-1s rather than oral options, suggesting that when price barriers are lowered, patients often prioritize clinical fit and familiarity with injections over route of administration. (2026-07-22)
Source: Reuters via Investing.com
Related on Metabolic Ledger: /cost/medicare-glp1-coverage
FDA approves Lipfendra, first oral PCSK9 inhibitor, expanding cardiometabolic options for GLP-1 users
FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with certain hypercholesterolemia profiles, including familial disease. While not a GLP-1, the drug offers an additional oral option for patients who often overlap with GLP-1 users in cardiometabolic risk, enabling more combination strategies for LDL reduction without adding another injection. (2026-07-17)
Source: FDA
Related on Metabolic Ledger: /after-glp1/glp1-and-cholesterol
Novo Nordisk contests what it calls misleading U.S. GLP-1 advertising campaigns by Eli Lilly
Novo Nordisk issued a statement saying it is taking action to stop what it characterizes as multiple misleading national GLP-1 advertising campaigns run by Eli Lilly. While the press item offers limited detail on specific claims, Novo positions the dispute as a push for accurate information on GLP-1 therapies, highlighting that competitive marketing around efficacy, safety, and convenience is increasingly subject to legal and regulatory challenge. (2026-07-21)
Source: Novo Nordisk
Related on Metabolic Ledger: /regulatory/fda-glp1-warning-letters-explained